| 000 | 01727 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250517055752.0 | ||
| 264 | 0 | _c20160719 | |
| 008 | 201607s 0 0 eng d | ||
| 022 | _a1476-5551 | ||
| 024 | 7 |
_a10.1038/leu.2015.283 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZeidan, A M | |
| 245 | 0 | 0 |
_aComparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. _h[electronic resource] |
| 260 |
_bLeukemia _cMar 2016 |
||
| 300 |
_a649-57 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAzacitidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aDecitabine |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xdiagnosis |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aSekeres, M A | |
| 700 | 1 | _aGarcia-Manero, G | |
| 700 | 1 | _aSteensma, D P | |
| 700 | 1 | _aZell, K | |
| 700 | 1 | _aBarnard, J | |
| 700 | 1 | _aAli, N A | |
| 700 | 1 | _aZimmerman, C | |
| 700 | 1 | _aRoboz, G | |
| 700 | 1 | _aDeZern, A | |
| 700 | 1 | _aNazha, A | |
| 700 | 1 | _aJabbour, E | |
| 700 | 1 | _aKantarjian, H | |
| 700 | 1 | _aGore, S D | |
| 700 | 1 | _aMaciejewski, J P | |
| 700 | 1 | _aList, A | |
| 700 | 1 | _aKomrokji, R | |
| 773 | 0 |
_tLeukemia _gvol. 30 _gno. 3 _gp. 649-57 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/leu.2015.283 _zAvailable from publisher's website |
| 999 |
_c25351381 _d25351381 |
||